Telehealth company Freddie acquired by Grindr for $250 million USD

Grindr Inc. is acquiring telehealth platform PurposeMed Inc. for $250M, including $190M in cash and $60M in stock, with an additional $70M possible in 2028. The deal is expected to close by Q4 2023. PurposeMed's HIV prevention service Freddie is projected to generate $80M in revenue by 2026. The acquisition aligns with Grindr's strategy to expand beyond dating into healthcare resources for the gay community.

Grindr has agreed to acquire PurposeMed, Freddie's parent company, for $250 million, including $190 million in cash and $60 million in shares, with an additional $70 million contingent on performance. The deal, expected to close in Q4 2026, will integrate PrEP care services into the Grindr app, offering users access to HIV prevention consultations, testing, and prescriptions.

Grindr is acquiring HIV prevention med provider Freddie for $250M in cash and stock, its first major acquisition. The deal aims to integrate PrEP medication into Grindr's platform, potentially at low or no cost, expanding beyond dating services. Freddie will merge with Grindr's existing telehealth arm, Woodwork, under Grindr Health. The company recently settled an HIV data-sharing lawsuit for £26M.

Grindr Inc. agreed to acquire PurposeMed Inc., parent of HIV-prevention platform Freddie, for $250M ($190M cash, $60M stock) with up to $70M in earnouts. The deal, expected to close Q4 2026, will create Grindr Health, merging Freddie and Woodwork. Freddie, serving 55,000 patients, projects $80M+ 2026 revenue. The acquisition aims to diversify Grindr's revenue streams and expand healthcare services.

Grindr plans to acquire Freddie, an LGBTQ+ digital health clinic, for $250 million. Freddie specializes in PrEP access and serves over 55,000 patients. Grindr aims to integrate Freddie's services into its platform, enhancing healthcare offerings. Grindr's stock fell 4.4% post-announcement.

Grindr shares fell 7.9% to $14.22 after announcing a $250M acquisition of PurposeMed Inc. The deal, funded by $190M cash and $60M stock, raised liquidity and dilution concerns. Analysts maintain positive ratings, but investors doubt the earnout and margin impact. Insider sales and market skepticism drove the decline.